NCT03482167

NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: University of Delaware · Academic / Other
• Sex: All
• Age: 60 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities. Overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related memory loss.

Conditions

• Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	Niagen®	250 mg capsules (4 capsules daily)
OTHER	Placebo	placebo

Timeline

• Start date: 2019-03-20
• Primary completion: 2024-01-08
• Completion: 2024-01-22
• First posted: 2018-03-29
• Last updated: 2025-04-04
• Results posted: 2025-04-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study